BIO International 2025: CEO Paul Hastings discusses the progress Nkarta is making on its NK cell approach to autoimmune conditions
Jun 17, 2025
09:21
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
He describes why he believes NK cells are better suited thank T-cells for autoimmune, and updates us on the company's clinical programs. Nkarta will share a data on everything before the end of the year.